183results about How to "Reduce induction" patented technology

A boost converter utilizing bi-directional magnetic energy transfer of coupling inductor provides a high efficiency boost DC-DC converting with above 30 times voltage boost rate, which uses a coupling inductor and low voltage switch to absorb circuit induction voltage of a passive regenerative snubber no matter if switch is turned on or off. Such that, a much higher voltage boost rate than the turn rate of transformer and wider range of switching duty cycle is obtained. A bi-directional magnetic energy path is utilized, that is, when switch is turned on the first winding of coupling inductor stores magnetic excited high current energy, and opposite magnetic flux is induced on the second winding at the same time. When switch is turned off the magnetic excited current continues and increases the voltage on the second winding. The second winding has bi-directional magnetic current induced and fully utilizes capacity of transformer's iron core.

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Disclosed are methods for suppressing the induction of inducible nitric oxide synthase in a cell comprising contacting said cell with an effective amount of at least one induction suppressor of inducible nitric oxide synthase or a cytokine are disclosed. The induction suppressor can be an inhibitor of mevalonate synthesis, an inhibitor of the farnesylation of Ras, an antioxidant, an enhancer of intracellular cAMP, an enhancer of protein kinase A (PKA), an inhibitor of NF-kβ activation, an inhibitor of Ras/Raf/MAP kinase pathway, an inhibitor of mevalonate pyrophosphate decarboxylase or an inhibitor of farnesyl pyrophosphate.

The present invention relates to a controlled drug release system in which a certain ratio or retinoic acid is incorporated into a microsphere comprising biodegradable polymer and amphoteric block copolymer having both hydrophilic and hydrophobic groups.

A magnetoresistive element includes magnetoresistive films each having an upper surface and a lower surface, and conductors combining the magnetoresistive films in series and including top electrodes and bottom electrodes. Each one of the top electrodes and corresponding one of the bottom electrodes oppose each other to sandwich corresponding one of the magnetoresistive films. Each electrode of the top electrodes and the bottom electrodes includes a stem section and a branch section, the stem section extending in a direction along a series alignment direction of the magnetoresistive films, and the branch section extending along the lamination plane in a direction intersecting a direction in which the stem section extends. The branch section in the top electrode is in contact with an upper surface of the corresponding magnetoresistive film, and the branch section in the bottom electrode is in contact with a lower surface of the corresponding magnetoresistive film.

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound, e.g., ABT-263, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

A liquid pharmaceutical composition comprises an aqueous medium having suspended therein a solid particulate Bc1-2 family protein inhibitory compound such as ABT-263, having a D₉₀ particle size not greater than about 3 μm; wherein the aqueous medium further comprises at least one pharmaceutically acceptable surfactant and at least one pharmaceutically acceptable basifying agent such as sodium bicarbonate in amounts that are effective together to inhibit particle size increase. The composition is suitable for oral or parenteral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bc1-2 family proteins, for example cancer.

Electric arc monitoring is effected by exploiting the discovery that electric arcs are fractal phenomena in that all essential information that signifies "arc" is contained in each fractal subset. These fractal subsets are logarithmically distributed over the arc spectrum. Monitoring of arcs is most advantageously effected on a fractal subset (16) of low logarithmic order where the amplitude is higher pursuant to the 1/f characteristic of electric arcs, where cross-induction among neighboring circuit is lower, and where travel between the arc (12) and the arc signature pickup (23) is longer than at the high frequencies customary for electric arc detection. Fractal subset transformation (17) reduces the danger of false alarms. Arc signature portions may be processed in out of phase paths (242, 342) or treated as modulated carriers (42) for monitoring. Aircraft may be equipped with spark monitoring systems (80) that record (82-86) occurence of dangerous sparking at different locations (92-96) aboard the aircraft (81).

A medical implantable lead is adapted to be implanted into a human or animal body for monitoring and/or controlling of an organ inside the body. The lead has in a distal end, a combined fixation means and electrode member in form of a helix, which is connected to a rotatable tubular member being connected to a rotatable member at a proximal end of the lead, and which is rotatable in relation to the lead and extendable out from the distal end, by rotation of the control member and the tubular torque transferring member, to be able to fixate the distal end of the lead to the organ by being screwed into the tissue. The helix is electrically connected to a connector at the proximal end by means of at least one electrically conducting wire formed as an electrically conducting coil, which is separate from the tubular torque transferring member and unrotatable in relation to the lead and that has one or more individual wires, each including an electrically conducting wire core and a surrounding electrically insulating layer, wherein the rotatable control member is rotatable within the connector.

A laminated coil includes a laminated body having magnetic body sections that are provided on both main surfaces of a non-magnetic body section and include a plurality of stacked magnetic layers, the non-magnetic body section including at least one non-magnetic layer, and a coil including helically connected coil conductors provided in the laminated body. The conductor width of at least one of the coil conductors provided inside the non-magnetic body sections and the coil conductors provided on both main surfaces of the non-magnetic body sections is greater than the conductor width of the other coil conductors in the laminated body.

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

The invention relates to certain compounds according to Formula (I):

or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders and immune disorders.

The present invention relates to a process for obtaining fatty acid esters from triglycerides by means of alcoholysis. In particular, the invention relates to a process for the transesterification of fat and/or oil by alcoholysis wherein, in order to accelerate the process in the initial stage, at least one alkanol fatty acid ester is added in a quantity such that the reaction mixture produced thereby consists of one phase. A high reaction rate can thereby be maintained in the process from the beginning.

The invention relates to a combination of multiple genetic single nucleotide polymorphisms and environmental factors related to a coronary heart disease and application of the combination. The genetic single nucleotide polymorphisms comprise the following locus: rs2123536, rs18422896, rs9349379, rs9268402, rs12524865, rs10757274, rs1333042, rs7136259 and rs11066280; and the environmental factors comprise individual smoking, drinking and body mass index information, and blood gloucose and high density lipoprotein cholesterol value in venous blood. Based on the combination factors, a prediction model for individual level coronary heart disease is established, and the combination of the multiple genetic single nucleotide polymorphisms and the environmental factors related to the coronary heart disease has an important application prospect in assessing the coronary heart disease risk for people.